Oculus Innovative Sciences, Inc. Files Registration Statement with the SEC for Proposed Initial Public Offering

PETALUMA, CA-- (July 5, 2006)—Oculus Innovative Sciences, Inc. announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission for an initial public offering of shares of its common stock.  A.G. Edwards will be the sole book-running manager, Jefferies & Company will be co-lead manager and First Albany Capital and C.E. Unterberg, Towbin will act as co-managers of the offering.

The proposed offering will be made only by means of a prospectus.  When available, copies of the preliminary prospectus can be obtained from A.G. Edwards & Sons, Inc., One North Jefferson Avenue, St. Louis, MO 63103, telephone: (314) 955-3000.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release does not constitute an offer to sell or the solicitation of any offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Oculus Innovative Sciences, Inc.
Oculus Innovative Sciences, Inc. is a medical technology company focused on the development, manufacture and commercialization of a family of products intended to prevent and eliminate infection in chronic and acute wounds. The Company's platform technology, called Microcyn®, is a non-toxic, super-oxidized, water-based solution that is designed to eliminate a wide range of pathogens including bacteria, viruses, fungi, spores and antibiotic-resistant strains of bacteria.   

(Download PDF: 128 KB)